Human coronary bare-metal stents (BMS) and drug-eluting stents (DES) from autopsy cases with implant duration Ͼ30 days were examined for the presence of neointimal atherosclerotic disease.
Percutaneous coronary interventions (PCI) involving stenting are the most widely performed procedures for the treatment of symptomatic coronary disease (1) . Although first-generation drug-eluting stents (DES), including sirolimus-eluting stents (SES [Cypher, Cordis Corp., Miami Lakes, Florida]) and paclitaxel-eluting stents (PES [Taxus, Boston Scientific, Natick, Massachusetts]), have radically reduced restenosis (2,3), complications of late stent thrombosis (LST) and very late stent thrombosis (VLST) have emerged as an important but small limitation to this technology.
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Both clinical imaging and autopsy studies suggest that the primary etiology of LST is the lack of complete endothelialization over stent struts. Interrogation of stented coronary arteries by angioscopy confirms that the incidence of uncovered struts in patients receiving DES is high, 20% at 2 years (4). However, the cause of LST is considered to be multifactorial, and other mechanisms in addition to delayed healing may be important in the pathophysiology of LST.
Although a thrombotic event related to atherosclerosis of native coronary vessels is a widely accepted cause of acute coronary syndromes and sudden death (5) , there is little information in reference to lesion morphologies that may contribute to thrombosis associated with stents. Chen et al. (6) have reported that a significant number of patients with bare-metal stents (BMS) and restenosis present with acute myocardial infarction or unstable angina, raising the question whether these events might be attributable to plaque rupture within the neointima. Although we have also reported a case of sudden coronary death caused by plaque rupture secondary to atherosclerotic change developing within the neointima of a BMS (7) , this phenomenon is believed to be rare and is thought to occur with extended implant durations beyond 5 years (8) . The incidence of atherosclerosis occurring within DES and BMS implants at autopsy has not been examined systematically. The present investigation represents a histopathological study of atherosclerosis occurring within BMS and DES implants focused on the incidence, character, and temporal development, in particular as an underlying cause for acute coronary thrombosis. Hearts with multiple stents, overlapping, and consecutively implanted stents were treated as 1 lesion, whereas stents including a gap of Ͼ5 mm were treated as separate lesions, as previously described (9) . The cause of death was reported as stent-related death (thrombosis and restenosis with or without diffuse coronary artery disease [CAD]), nonstent-related cardiac death, and noncardiac death as previously defined (9) . All available clinical records were reviewed for the duration of implant, risk factors, and mechanism of death. Histologic preparation. Hearts with stented arteries were fixed in 10% neutral buffered formalin, dissected off the heart, radiographed, and submitted for plastic embedding in methylmethacrylate. Coronary arteries were segmented at 2-to 3-mm intervals, and histologic sections were cut at 6 m and stained with hematoxylin-eosin and Movat pentachrome, as previously described (9) . Pathologic assessment. Acute thrombosis was defined as a platelet-rich thrombus occupying Ͼ30% of the crosssectional area of the lumen, and stent restenosis was defined as Ͼ75% cross-sectional area narrowing by neointimal formation. The native plaques (outside stent struts) were assessed and classified using our modified American Heart Association classification, to include traditional definitions of pathological intimal thickening, fibroatheroma, thin-cap fibroatheroma, and plaque rupture. Fibrotic lesions with or without calcification that did not show macrophage infiltration were noted separately (5). Atherosclerosis of the neointima within the stent was defined as peristrut foamy macrophage clusters with or without calcification, fibroatheromas, thin-cap fibroatheromas, and ruptures with thrombosis. In all cases, there was no communication of the lesion within the stent with the underlying native atherosclerotic plaque.
Methods

Patients and lesions. All available material from the
Immunohistochemistry for the identification of macrophages was carried out in selected cases using a CD68 antibody (dilution 1:800, Dako, Carpinteria, California), as previously described (10) . The primary antibody was labeled using an LSAB kit (Dako) and positive staining visualized by a 3-amino-9ethyl carbazole (AEC) substratechromogen system with Gill's hematoxylin as a counterstain.
The data were analyzed on the basis of lesions and not by patients, as often the duration of multiple stents varies as patients undergo repeat PCI dictated by the onset of symptoms. The development of atherosclerotic change by duration of stent implantation was also assessed in addition to the regional placement of the stent. Statistical analysis. Continuous variables with normal distribution were expressed as mean Ϯ SD. Variables with non-normal distribution were expressed as median (interquartile range [IQR] ). Comparisons of continuous variables with normal distribution were tested by Student t test. A Wilcoxon rank-sum test was used for comparisons of non-normally distributed continuous variables. Categorical variables were compared using the chi-square test. Normality of distribution was tested with the Wilk-Shapiro test. Multiple logistic generalized estimating equations (GEE) modeling (9) was performed to identify the determinants of stent neoatherosclerosis, in which age, sex, and significant variables (p Ͻ 0.05) among lesion characteristics (the number of stents, stent duration, indication of stent implantation, lesion location, stent length, overlapping stents, underlying plaque morphology, and stent type) in univariate analysis were entered as independent variables. The GEE modeling was necessary because of the clustered nature of Ͼ1 stented lesions in some cases, resulting in unknown correlations among measurements within lesion clusters. A value of p Ͻ 0.05 was considered statistically significant.
Results
Patient characteristics. Age, sex, and coronary risk factors were similar for patients receiving BMS or DES ( (20) 14 (17) 18 (24) Ͻ 0.001
Restenosis without diffuse CAD 19 (13) 5 (3) 2 (2) 3 (4) 0.001
Diffuse CAD with restenosis 20 (14) 4 (3) 3 (4) 1 (1 (4) 10 (6) 5 (6) 5 (7) 0.411
Values are expressed as means Ϯ SD or n (%). *Among 5 patients with thrombosis in the BMS group, 4 patients had neointimal plaque rupture and 1 patient had restenosis only. †Among 32 patients with thrombosis in the DES group, 1 patient had neointimal plaque rupture, 2 patients had restenosis, and the rest had uncovered struts from varying etiologies. BMS ϭ bare-metal stent(s); CABG ϭ coronary artery bypass graft surgery; CAD ϭ coronary artery disease; DES ϭ drug-eluting stent(s); PES ϭ paclitaxel-eluting stent(s); SES ϭ sirolimus-eluting stent(s). 
Lesion Characteristics
Incidence of neoatherosclerosis.
Representative images of newly formed atherosclerotic changes within the neointima in various stents are shown in Figure 1 . Notably, 85% (177 lesions) DES were implanted for 2 years or less with no lesions extending beyond 6 years, while 45% (88 lesions) BMS were implanted for 2 years or less and 17% (33 lesions) had durations of Ͼ6 years ( Table 3 ). The incidence of any neoatherosclerosis was greater in DES (n ϭ 64, 31%) than BMS (n ϭ 31, 16%) lesions (p Ͻ 0.001). Nearly one-half the DES lesions with neoatherosclerosis (31 of 64 lesions, 48%) contained peristrut foamy macrophage clusters, and the other half showed fibroatheromas. A significant temporal relationship was found among BMS and DES; atherosclerotic change occurred in significantly shorter implant durations for DES than for BMS (DES, 420 days [IQR: 
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Neoatherosclerosis in BMS and DES 361 to 683 days]; BMS, 2,160 days [IQR: 1,800 to 2,880 days]; p Ͻ 0.001) ( Table 3 ). The earliest implant duration showing early atherosclerotic change characterized by foamy macrophage clusters was observed at 70 days for PES and 120 days for SES, whereas its occurrence in BMS was found much later, at 900 days. Similarly, the earliest implant durations for lesions with necrotic cores were relatively short in DES: at 270 days and 360 days for SES and PES, respectively, whereas the earliest duration for necrotic core formation in BMS was longer, 900 days. Representative images of fibroatheroma with necrotic core from a PES implant of 14 months' duration is illustrated in Figures 2A,  2B , and 2C. The cumulative incidence of any neoatherosclerotic change relative to implant duration is shown in Figure 3 , and is significantly higher in DES as compared with BMS. Notably, the incidence of neoatherosclerosis in BMS does not catch up to DES despite the longer durations of stent implantation beyond 6 years. The incidence of neoatherosclerosis was also evaluated based on the implant duration (Table 3) . For those implants of Յ2 years, the DES group had a greater incidence of any neoatherosclerosis (DES 29% vs. BMS 0%, p Ͻ 0.001), which was represented by a greater incidence of foamy macrophage clusters (DES 14% vs. BMS 0%, p Ͻ 0.001) as well as fibroatheromas (DES 13% vs. BMS 0%, p Ͻ 0.001). For durations between 2 years and 6 years, the DES group still expressed a higher incidence of neoatherosclerosis (DES 41% vs. BMS 22%, p ϭ 0.053) ( Table 3 ). The incidence of any neoatherosclerotic change was greater in SES than in PES for implant durations of 2 years or less (SES 37% vs. PES 21%, p ϭ 0.021), although differences did not remain with stents implanted for 2 to 6 years (SES 44% vs. PES 38%, p ϭ 0.719).
In regard to the location of the stent and the development of atherosclerosis, the incidence of atherosclerotic change in proximal lesions was significantly higher than those in mid/distal lesions in BMS (27% vs. 12%, respectively; p ϭ 0.014); however, this difference was not seen in DES (33% vs. 30%, p ϭ 0.611) ( Table 3) .
More advanced lesions-unstable plaque, namely, thincap fibroatheroma and ruptured plaques with thrombosis (Figs. 2D to 2I)-were seen for both BMS (n ϭ 7, 4%) and DES (n ϭ 3, 1%), where the majority of BMS were Ͼ5 years (average implant duration 6.1 Ϯ 1.5 years) whereas for DES, unstable neoatherosclerotic lesions were identified with devices implanted Յ2 years (1.1, 1.4, and 1.9 years) . Details of the 10 patients (7 BMS and 3 DES) with thin-cap fibroatheroma or plaque rupture within the instent neointima are provided in the visual Table 4 . The incidence of neoatherosclerosis did not differ between patients with stent-related death and patients with nonstent-related death, both in BMS (18% vs. 20%, p ϭ 0.848) and in DES (27% vs. 42%, p ϭ 0.099). In patients with stent-related death, the incidence of neoatherosclerosis was comparable between BMS and DES (18% vs. 27%, p ϭ 0.339), whereas in patients with nonstent-related death, DES had a higher incidence of neoatherosclerosis than BMS (42% vs. 20%, p Ͻ 0.001).
Incidence of Neoatherosclerosis Stratified by Duration of Implant
A multiple logistic GEE modeling identified younger age (odds ratio (Table 5) .
Discussion
The present study suggests that in-stent neoatherosclerosis occurs in both BMS and DES; however, for DES implants, it is observed more frequently and at an earlier time point (median 420 days) as compared with BMS (median 2,160 days). For stent-related deaths, in-stent neoatherosclerosis incidence was similar for BMS and DES (18% vs. 20%). However, for nonstent-related death, the incidence of neoatherosclerosis was more frequent for DES than BMS (42% vs. 20%, p Ͻ 0.001). Moreover, neoatherosclerosis in DES shows unstable characteristics by 2 years after implant, whereas similar features in BMS occur at relatively later times (average implant duration 6 years). These observa- Table 4 ) who had a BMS implanted 8 years before death. Note occlusive thrombus (Th) in the lumen and ruptured plaque (boxed area), which is shown at higher magnification in H with large number of macrophages within the lumen as well as at the ruptured cap. (I) Note large number of CD68-positive macrophages at the site of rupture. Abbreviations as in Figure 1 .
Nakazawa et al. March 15, 2011 March 15, :1314 Neoatherosclerosis in BMS and DES tions raise the question whether neoatherosclerosis seen within DES as well as BMS at follow-up may in part be responsible for some late thrombotic events. The implications of current findings may be of practical importance as the usage of DES implants continues to increase worldwide. The occurrence of uncovered struts complicated by a dysfunctional endothelium remains the primary cause of LST in DES; nevertheless, the present study adds another risk factor, namely, in-stent plaque rupture, although a rare event.
Although the underlying processes responsible for the development of neoatherosclerosis after stent implantation are likely multifactorial, we hypothesize that it may involve the inability to maintain a fully functional endothelialized luminal surface within the stented segment (11) . The endothelium normally provides an efficient barrier against the excessive uptake of circulating lipid, and that may no longer be true in the in-stent regions of DES and BMS (12) . In the present study, BMS exhibited greater trends for neoatherosclerotic changes occurring in the more proximal than distal lesions relative to DES, thus indicating divergent mechanisms by which neoatherosclerosis attributed to DES may be more related to incompetent and incomplete endothelialization as opposed to shear stress for BMS. These findings in the BMS may be more akin to the development of atherosclerosis in native coronary arteries, and is most prominent in the proximal regions of the coronary arteries (13) .
Recently, chronic endoplasmic reticular stress in endothelial cells at athero-susceptible sites with arterial flow disturbances has been linked to inflammation (14) . Shearinduced changes in endothelial phenotype (collectively known as mechanotransduction) may promote the expression of transmembrane proteins, like integrins and platelet endothelial cell adhesion molecule-1, which further allow inflammatory cell attachment and migration to subendothelial spaces (13) . Changes in endothelial cell permeability could presumably allow greater amounts of lipoproteins to enter the subendothelial space, with an affinity for matrix proteins, in particular proteoglycans that promote their retention (15) .
The relatively faster development of neoatherosclerosis in DES than in BMS is probably related to drug effects, which are also responsible for incomplete endothelialization. Previous animal studies of DES (11) suggest that the regenerating endothelial lining could be incompetent, and therefore may result in endothelial cells activation, which leads to monocyte adherence with subsequent subendothelial migration. Incomplete (delayed) endothelial regrowth and recovery observed with SES or PES that may contribute to atherogenesis is characterized by poor cell-to-cell contacts identified by decreased expression of platelet endothelial cell adhesion molecule-1 and antithrombotic mediators such as thrombomodulin (11) .
Experimental evidence suggests that neoatherosclerosis within stents can be associated with delayed arterial healing compounded by lethal injury to smooth muscle cells and endothelial cells. We have reported that a 32 P ␤-emitting stent implanted, with activities ranging from 6 Ci to 48 Ci, showed focal evidence of atherosclerotic change in normal arteries of New Zealand White rabbits examined at 6 and 12 months (16). Considering it is well known that atherosclerosis does not develop in normal arteries of the rabbit in the absence of hypercholesterolemia, these results suggest that the atherogenic process is inherent to process occurring within the stent itself.
In humans, 2 pathology studies have reported neoatherosclerotic change occurring in vein graft and in native coronary arteries with foam cell infiltration after BMS implants (17, 18) . Previous clinical studies have also suggested endothelial dysfunction after SES implantation by showing impaired vasomotor function in the adjacent segment of stents (19) , although the precise mechanism for the endothelial dysfunction in the stented segment in humans remains unknown. Clinical relevance. Coronary SES implants in 57 patients recently interrogated by angioscopy showed a 35% increase in the maximum yellow color of the neointima within 10 months of follow-up (20) . Even among lesions that did not express yellow plaque at baseline, yellow color was detected in 95% of SES implants, suggesting a neoatherosclerotic change in response to the stent.
A retrospective analysis of 4,503 patients with at least 1 BMS implant, reported by Doyle et al. (21) , showed that the incidence of stent thrombosis was 0.8% at 1 year and 2% at 10 years, which is lower than reported for DES (SES and PES), 2.9% at 3 years, involving an all-comer registry of 8,146 patients (22) . In contrast, a meta-analysis of 18,023 patients reported by Stettler et al. (23) revealed that mortality risks were similar between BMS and DES (SES and PES), although several trials included in the meta-analysis evaluated only cardiac and not all-cause mortality. The Key Words: bare-metal stent y drug-eluting stent y neoatherosclerosis y pathology. 
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